Sugi Predict

Sugi Predict / Compounds / SCHEMBL309597

SCHEMBL309597

SCHEMBL309597

CC(C)(O)C(C)(C)OB(O)c1ccc2scnc2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 4/20 0.34
▸ LCK P06239 2/20 0.34
▸ KDR P35968 2/20 0.34
▸ TGFBR1 P36897 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ PTK6 Q13882 2/20 0.32
▸ HSD11B1 P28845 1/20 0.32
▸ ALOX5AP P20292 1/20 0.31
▸ FEN1 P39748 1/20 0.31
▸ FFAR1 O14842 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ HKDC1 Q2TB90 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2780359 0.77 ALDH1A1 (0.35) ALDH1A1HSD17B10SMN1; SMN2KDM4ENPC1
SCHEMBL16734315 0.76 MEN1 (0.36) ALDH1A1HSD17B10SMN1; SMN2NPSR1KDM4E
SCHEMBL6606924 0.75 PTPRC (0.35) —
SCHEMBL1094988 0.74 ALDH1A1 (0.45) RIPK2LCKKDRTGFBR1ALDH1A1
SCHEMBL15738835 0.73 SMN1; SMN2 (0.44) ALDH1A1HSD17B10SMN1; SMN2KDM4ENPC1
SCHEMBL2361665 0.73 MMP12 (0.34) ALDH1A1KDM4ETDP1
SCHEMBL789412 0.73 ALDH1A1 (0.43) ALDH1A1
SCHEMBL153508 0.70 ALDH1A1 (0.43) ALDH1A1HSD17B10MAPK1SMN1; SMN2KDM4E
SCHEMBL1118010 0.70 UHRF1 (0.36) —
SCHEMBL12816668 0.70 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119176814-A PRMT5 inhibitor and application thereof 艾立康药业股份有限公司 2024-12-24 — — CN disclosed
EP-4339193-A1 COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF Innovstone Therapeutics Limited (CN) 2024-03-20 — — EP disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 — — EP disclosed
US-11566025-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-01-31 — — US disclosed
CN-115340528-A Compound with anti-tumor activity and application thereof 上海翊石医药科技有限公司 2022-11-15 — — CN disclosed
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof Beijing Adamadle Biotechnology Limited Liability Company (CN) 2022-06-07 — — US disclosed
CN-108707139-B Aminopyrimidine compound and preparation method and application thereof 北京鞍石生物科技有限责任公司 2021-04-06 — — CN disclosed
CN-105283451-B Novel inhibitors of viral replication 鲁汶天主教大学 2021-01-26 — — CN disclosed
EP-2978753-B1 NOVEL VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2020-08-12 — — EP disclosed
US-20200223845-A1 NOVEL VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2020-07-16 — — US disclosed
US-10351552-B2 Bicyclic antiparasitic compounds MediSynergies, LLC (US) 2019-07-16 — — US disclosed
US-20190177304-A1 Bicyclic Antiparasitic Compounds MediSynergics, LLC (US) 2019-06-13 — — US disclosed
US-20160297810-A1 NOVEL VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2016-10-13 — — US disclosed
EP-2978753-A1 NOVEL VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven (BE) 2016-02-03 — — EP disclosed
WO-2014154682-A1 NOVEL VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2014-10-02 — — WO disclosed
US-8093253-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 — — US disclosed
CN-101970401-A Leukotriene b4 inhibitors HOFFMANN LA ROCHE 2011-02-09 — — CN disclosed
EP-2250150-A1 LEUKOTRIENE B4 INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-11-17 — — EP disclosed
WO-2009109483-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 — — WO disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351552-B2 Bicyclic antiparasitic compounds TBCA, NAT1, HDAC1 RIPK2 4686/4885LCK 4062/4885KDR 4817/4885
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S RIPK2 3995/4885LCK 3119/4885KDR 4555/4885
US-11566025-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 RIPK2 3094/4885LCK 2390/4885KDR 1558/4885
US-20160297810-A1 NOVEL VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, IRF3 RIPK2 2697/4885LCK 2906/4885KDR 1153/4885
US-20190177304-A1 Bicyclic Antiparasitic Compounds TBCA, NAT1, HDAC1 RIPK2 4686/4885LCK 4062/4885KDR 4817/4885
US-20200223845-A1 NOVEL VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, IRF3 RIPK2 2697/4885LCK 2906/4885KDR 1153/4885
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof WEE1, WEE2, EGFR RIPK2 2465/4885LCK 9/4885KDR 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.